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ABSTRACT: Aging can lead to decline in cognition, notably due to neurodegenerative processes overwhelming 
the brain over time.  As people live longer, numerous concerns are rightfully raised toward long-term slowly 
incapacitating diseases with no cure, such as Alzheimer’s disease.  Since the early 2000’s, the role of 
neuroinflammation has been scrutinized for its potential role in the development of diverse neurodegenerative 
diseases notably because of its slow onset and chronic nature in aging.  Despite the lack of success yet, treatment 
of chronic neuroinflammation could help alleviate process implicated in neurodegenerative disease.  A growing 
number of studies including our own have aimed at the endocannabinoid system and unfolded unique effects of 
this system on neuroinflammation, neurogenesis and hallmarks of Alzheimer’s disease and made it a reasonable 
target in the context of normal and pathological brain aging. 
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Alzheimer’s disease (AD) is the most common 
neurodegenerative disease and accounts for the majority 
of diagnosed dementia after age 60. It is estimated to 
currently affect between 20 and 30 million people 
worldwide with an incidence of the disease between 3 and 
30% over the age of 60 [1]. As life expectancy increases, 
the prevalence of AD and its burden on healthcare is very 
likely to increase dramatically in the next few decades. 
Currently available drugs do not reverse or stop the 
progression of the disease, but only relieve certain 
cognitive symptoms and thus provide no cure for this 
growing health and economic concern. 
 
Alzheimer’s disease 
 
The disease is characterized by a slow but progressive loss 
of cognitive functions associated with neurodegeneration, 
as well as an important neuroinflammation [2]. More 
classically, AD is described mainly by two post-mortem 
histological diagnostic features that are extracellular 
amyloid  protein (A deposition and Tau 
hyperphosphorylation forming intracellular 
neurofibrillary tangles (NFT) [3–5]. Mutations in the 
genes coding for amyloid precursor protein (APP), 
presenilin-1 or -2 (PSEN1, PSEN2) have been identified 
as implicated in familial forms of AD and are known to 
favour the production of different Aβ oligomeric 
assemblies and amyloid plaques in various region of the 
brain, notably the hippocampus, cortex and amygdala. 
This broadly accepted hypothesis, known as the amyloid 
cascade, states that the cause of AD pathophysiology is 
the massive production of Aβ following cleavage of the 
APP by β-secretase and γ-secretase complex successively 
[6]. It also implies that all other hallmarks (inflammation 
and Tau hyperphosphorylation notably) are direct 
consequences of A exacerbated production. Nonetheless 
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Tau proteins when hyperphosphorylated can form NFT 
that in turn impair intra-neuronal communication [7] and 
lead directly to cell death [5]. Although the amyloid 
cascade hypothesis is strongly supported, particularly in 
the familial forms of the disease that account for less than 
5 per cent of all cases, increasing evidence suggests that 
the evolution/causes of the sporadic forms of the disease 
are different from the familial ones [8]. 
Indeed, another important feature of AD’s pathology 
is the presence of a chronic inflammatory component. 
Several reviews over the last decade have extensively 
summarized those events [2,9]. If inflammatory processes 
are well known to accompany tissue damage in many 
neurodegenerative diseases as Parkinson’s [10] or 
amyotrophic lateral sclerosis [11], AD’s progression 
seems to be tightly linked to chronic inflammation. In fact, 
strong epidemiological evidence suggests inflammatory 
processes as partly responsible for the development of 
AD. For example, long-term use of non-steroidal anti-
inflammatory drugs (NSAID) lowers the prevalence of 
AD by 30-60% [12–14]. Furthermore, biochemical 
analysis of AD brains revealed elevated levels of pro-
inflammatory cytokines such as IL-1, IL-6, TNF- or 
S100 [2,15]. On an histological point of view, gliosis 
(astrocytosis as well as microgliosis) is prominent and 
most plaques are surrounded by activated astrocytes 
and/or invaded by activated microglia [16,17]. A lot of the 
studies have focused on microglial cells, but it is now 
clear that microglial cells are assisted by astrocytes and 
endothelial cells [18] to maintain a chronic inflammatory 
state of the brain. This long lasting process (probably 
established over decades in the human brain) induces a 
chronic “stress” on neurons and affects their normal range 
of functioning. It has been clearly established that cell 
cycle proteins are activated [19], reactive oxygen species 
produced [19], mitochondrial function reduced [21] and 
denditric/axonal transport impaired [20].  
Although numerous studies have validated 
inflammatory mediators or the brain’s immune system in 
AD, the precise role of inflammatory processes in the 
disease pathophysiology is still highly controversial (from 
beneficial to possibly triggering AD [21,22]. As 
mentioned above, McGeer and coll. provided first support 
for a key role of inflammation in AD through a meta-
analysis of 17 epidemiological studies, indicating that 
NSAIDs might decrease the risk of AD [12]. This has 
been followed by other epidemiological studies reporting 
that elevated levels of inflammatory factors (such as IL-6 
and C-reactive protein notably) could be found in the 
plasma of AD patients long before clinical onset of the 
disease [23,24]. Moreover, diagnosis of dementia was 
more likely to be done during infection episodes [25]. 
Following such evidence, clinical trials however failed to 
show a beneficial effect of anti-inflammatory drugs in 
patients with symptomatic AD or mild cognitive 
impairment [26,27]. Based on the assumption that 
treatment needed to be timely, extended treatment of 
asymptomatic individuals with naproxen reduced the 
incidence of AD, supporting a benefit when NSAIDs are 
administered in early asymptomatic phases of the disease 
[28]. Moreover, some patients with high plaque burden 
exhibit no dementia [29] and also demonstrate almost no 
evidence of neuroinflammation or neurodegeneration 
[30]. This actually is in accordance with observations 
made in several transgenic mouse models of AD often 
devoid of strong neuroinflammatory response or 
neurodegeneration [31]. Finally, studies using non-
invasive brain imaging (MRI or PET) revealed that 
decrease in cognition performance in patients with AD is 
rather correlated with increased microglial activation, 
than with Aβ load [32,33]. 
On a cellular point of view, microglia is commonly 
accepted as recruited to clear Aβ aggregates even if 
ablation of microglia in an AD mouse model wasn't found 
to change disease progression [34,35]. On the other end, 
microglia might also be primarily recruited to clear debris 
from neurons and neurites within plaques [36], Aβ 
aggregates included in the process. Finally, aged 
microglia may become senescent and its response non-
appropriate in normal/pathological conditions [37], 
potentially explaining the role of inflammation early in 
the pathogenesis of AD. In particular, its hyper-active 
state and sustained secretion of pro-inflammatory 
elements may lead to inefficient clearance of degenerating 
cells, leading to an overall toxic microenvironment prone 
to further degeneration and aggregate of proteins in the 
extracellular space. 
Overall, it seems clear that neuroinflammation plays 
an important role in AD and that it may even influence 
disease progression very early on, especially as AD is 
diagnosed rather late while the mechanisms leading to 
neurodegeneration are already in motion probably 
decades before. To support this assumption, recent work 
from Knuesel's laboratory showed that chronic 
inflammation caused by viral infection with PolyI:C 
during the foetal period of non-transgenic animals can 
lead to very early changes in APP cleavage suggesting 
that neuroinflammation could trigger AD-like pathology 
in those animals [38].  
Cannabinoids  
The field of cannabinoid research has flourished over the 
past decades and have brought to light numerous 
functions of this system in normal and pathological 
conditions. So far two types of cannabinoid receptors have 
been identified, CB1 and CB2 [39,40].  Nonetheless other 
receptors are responsive to cannabinoids compounds: 
transient receptor potential vannilloid-1 (TRPV1), 
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peroxisome proliferator-activated receptors  and  
(PPAR, PPAR, see [41] for review). Discovery of 
cannabinoid receptors (CBr) lead to the finding of 
endogenous agonists for these receptors called 
endocannabinoids (EC).  In the central nervous system 
(CNS), CB1 is overwhelmingly represented over CB2, 
and the most abundant G protein-coupled receptors in the 
brain. CB1 is found in neurons and glial cells and 
particularly abundant in cortical regions, the 
hippocampus, cerebellum and basal ganglia [42]. It 
regulates numerous cerebral functions ranging from pain 
perception, motor control and feeding to emotion and 
memory processes. CB2 on the other end may be 
restricted to microglia [43] or neurons in the brainstem 
[44] and cerebellum [45]. Endocannabinoids are mostly 
derived from arachidonic acid, arachidonoylethanolamide 
(anandamide), and 2-arachidonoyl glycerol (2-AG), 
synthesized on-demand post-synaptically and released 
following calcium influx [46]. These EC in combination 
with the two known CBr constitute the endocannabinoid 
system (ECS). Deactivation of EC is rapid and due to 
enzymatic degradation in the synaptic cleft or reuptake 
[47]. The ECS is thought to be a neuromodulator [48] and 
an immunomodulator [49]. Cannabinoids demonstrated 
neuroprotective properties in numerous experimental 
conditions, some been or currently evaluated in various 
diseases ranging from cancer to AIDS for their peripheral 
analgesic and immunosuppressive properties [50,51].  
Moreover, their anti-inflammatory properties could prove 
beneficial in the treatment of multiple sclerosis, 
Parkinson’s disease and AD [52–57]. 
 
Cannabinoids and Alzheimer’s disease 
 
A growing amount of evidence points out to the possible 
implication of the ECS in the regulation of events 
occurring during the course of AD progression, 
particularly on the regulation of amyloid clearance and 
inflammation.  Post-mortem analysis of AD brains 
demonstrated changes in the expression of CB1 but those 
remains still unclear. Some authors witnesses reduction of 
CB1 expression in cortical areas [58,59], a finding that is 
similar to that seen in aged rats [54], while others 
demonstrated no changes in the cortex or hippocampus of 
AD patients [60–63]. Moreover, CB1 levels do not 
correlates with AD markers or cognitive status [59]. On 
the other hand, CB2 increase has been clearly identified, 
notably located on microglia within the amyloid rich 
plaques [58,59] and Solas and coll. correlated level of 
CB2 receptors with A42 level and plaques [59]. 
Moreover, up-regulation of the fatty acid amide hydrolase 
occurs within plaques and might be responsible for 
increase in metabolites from anandamide degradation, 
such as arachidonic acid, and thus contribute to the 
inflammatory process seen in AD [60].  
Several reports over the last two decades demonstrate 
the potential benefits from the modulation of the ECS over 
amyloid  and Tau hyper-phosphorylation. In vitro 
studies demonstrated benefits of the use of different EC 
on cell survival following Aexposition [64–67] and on 
Tau hyper-phosphorylation [68]. Morevover, A infusion 
in vivo (in rats and mice) is associated with gliosis and 
memory impairment, effects that can be reversed by 
diverse CB1, CB2 or mixed activation [58,69–73].  Two 
groups in Spain (De Ceballos and Ferrer’s laboratories) 
have also demonstrated the cognitive benefits of chronic 
infusion of EC in transgenic mice model of AD [74–76]. 
Ferrer’s group in particular also showed that chronic 
infusion of a CB1 or CB2 agonist could decrease Tau 
hyper-phosphorylation in APP/PS1 mice model of AD 
[74,75]. Nonetheless, most studies looking at the 
modulation of neuroinflammation using cannabinoids 
have mainly focused on CB2 receptors as they are mostly 
expressed on microglial cells. Studies mentioned earlier 
[58,68,69,71] have observed reduction in microglial 
activation and pro-inflammatory cytokines following 
infusion of A in rodents. But as in many studies on AD 
rodent models, those studies have difficulty pointing out 
if CB2 modulation benefits come from the reduction of 
neuroinflammatory processes per se or by the reduction 
of A activation of the neuroinflammatory system. Our 
lab did provide some potential clues on the role of the 
different CB receptors in this context. Indeed, our work 
demonstrated the anti-inflammatory potential using WIN-
55,212-2 chronically on chronic neuroinflammation in 
young and aged rats [54,56,77] as well the neurogenic and 
cognitive effect of WIN-55,212-2 in aged animals [55]. 
Our data suggested that the anti-inflammmatory effect of 
WIN-55,212-2 could be due to its activity on TRPV1 
receptors and its neurogenic effects linked to both CB1 
and CB2 receptor. 
 
Conclusion 
 
Because of the complexity of pathological mechanisms 
involved in AD progression, a multi-drug approach seems 
to emerge as a better potential alternative as none of the 
available drug therapies are capable of altering the 
progression of the disease.  The pleiotropic effects of 
cannabinoids, the numerous specific pharmacological 
tools to target its receptors and the growing number of 
pre-clinical effects on AD rodent models should finally 
raise the interest of the research community and be seen 
as a valuable alternative to slow disease progression or 
reduce some of the cognitive symptoms in AD.  
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